1.94
Precedente Chiudi:
$2.03
Aprire:
$2.03
Volume 24 ore:
510.03K
Relative Volume:
0.48
Capitalizzazione di mercato:
$351.29M
Reddito:
$109.16M
Utile/perdita netta:
$-107.78M
Rapporto P/E:
-1.7536
EPS:
-1.1063
Flusso di cassa netto:
$-95.45M
1 W Prestazione:
-7.18%
1M Prestazione:
-2.02%
6M Prestazione:
-29.96%
1 anno Prestazione:
+282.12%
Century Therapeutics Inc Stock (IPSC) Company Profile
Nome
Century Therapeutics Inc
Settore
Industria
Telefono
215-981-4000
Indirizzo
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
IPSC
Century Therapeutics Inc
|
1.94 | 367.58M | 109.16M | -107.78M | -95.45M | -1.1063 |
|
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
|
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-25 | Iniziato | TD Cowen | Buy |
| 2024-08-08 | Iniziato | Rodman & Renshaw | Buy |
| 2023-08-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-12-27 | Iniziato | Chardan Capital Markets | Buy |
| 2022-10-31 | Iniziato | Guggenheim | Buy |
| 2022-10-10 | Iniziato | Canaccord Genuity | Buy |
| 2022-05-23 | Iniziato | H.C. Wainwright | Buy |
| 2022-05-12 | Iniziato | William Blair | Mkt Perform |
| 2021-07-13 | Iniziato | BofA Securities | Buy |
| 2021-07-13 | Iniziato | JP Morgan | Overweight |
| 2021-07-13 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Century Therapeutics Inc Borsa (IPSC) Ultime notizie
Century Therapeutics (IPSC) awards 148,000 options vesting over 3 years - Stock Titan
Century Therapeutics' SVP Finance Carr Douglas Sells 254 Shares at $2.05 Each (NASDAQ: IPSC) - Kalkine Media
Century Therapeutics SVP sells $520 in stock for tax withholding By Investing.com - Investing.com Australia
Century Therapeutics appoints iECURE CEO Joseph Truitt to board - Bitget
Century Therapeutics Adds Joseph Truitt to Board of Directors - Minichart
Century Therapeutics CEO Brent Pfeiffenberger Withholds Shares for Tax on RSU Vesting - Kalkine Media
Century Therapeutics CTO Gregory Russotti Executes Automatic Sale of 534 Shares for Tax Withholding - Kalkine Media
Century Therapeutics SVP sells $520 in stock for tax withholding - Investing.com
Century Therapeutics Adds Director, Advances Cell Therapy Pipeline - TipRanks
Century Therapeutics (IPSC) CEO shares withheld for taxes on RSU vesting - Stock Titan
Tax-withholding sale trims Century Therapeutics (NASDAQ: IPSC) insider by 534 shares - Stock Titan
Automatic tax sale leaves Century Therapeutics (NASDAQ: IPSC) SVP with 504,565 shares - Stock Titan
Century Therapeutics appoints Joseph Truitt to board By Investing.com - Investing.com India
Century Therapeutics adds director, sets 2026 trial timelines - Stock Titan
Century Therapeutics Appoints Joseph Truitt to Board of Directors - Yahoo Finance UK
Century Therapeutics (NASDAQ: IPSC) officer plans stock sale partly to cover taxes - Stock Titan
Century (IPSC) Earnings Reading: EPS Beats Its Estimate at the Close; Share Move: The Stock Records a 4.27% Decrease in Latest TradingGuidance vs Actual - vinanet.vn
Century Targets FDA Filing for Diabetes Cell Therapy - MyChesCo
Century Therapeutics CEO Brent Pfeiffenberger Completes RSU Tax Withholding Share Transaction - Kalkine Media
Century Therapeutics (IPSC) CEO stock withheld for taxes - Stock Titan
Mizuho Securities Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $8 - Moomoo
HC Wainwright Issues Pessimistic Forecast for IPSC Earnings - MarketBeat
IPSC Q1 2026 Earnings: Narrower-Than-Expected Loss Yields 31.76% EPS SurpriseMid-Term Outlook - vinanet.vn
TD Cowen Maintains Century Therapeutics(IPSC.US) With Buy Rating - Moomoo
Century Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Century Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Century Therapeutics (NASDAQ:IPSC) Issues Quarterly Earnings Results - MarketBeat
Century Therapeutics Announces Q2 2026 Financial Results and Updates Investor Presentation in 8-K Filing - Kalkine Media
Form 8K Century Therapeutics Inc For: 12 August - Investing.com India
Century Therapeutics Reports Q2 Results, Pipeline Advancements - TipRanks
Form 8K Century Therapeutics Inc For: 12 August By Investing.com - Investing.com Canada
Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates - The Manila Times
Century Therapeutics posts $34.6 million Q2 loss as cash runway reaches 2029 - Quiver Quantitative
Century Therapeutics 2Q 2026: Revenue $0 EPS $(0.17) — 10-Q Summary - TradingView
Century Therapeutics Q2 net loss misses estimates on lease termination loss - TradingView
Century Therapeutics (IPSC) books $34.6M loss but holds $197M cash - Stock Titan
We Think Century Therapeutics (NASDAQ:IPSC) Needs To Drive Business Growth Carefully - Moomoo
Century Therapeutics (IPSC) Projected to Announce Earnings on Thursday - MarketBeat
Century Therapeutics (IPSC) SVP has automatic share sale to cover RSU taxes - Stock Titan
Seven Fleet Capital Management LP Takes Position in Century Therapeutics, Inc. $IPSC - MarketBeat
DV Trading LLC Makes New Investment in Century Therapeutics, Inc. $IPSC - MarketBeat
Century Therapeutics Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView
Century Therapeutics, Inc. (NASDAQ:IPSC) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Century Therapeutics Inc (IPSC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Century Therapeutics Inc (IPSC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Commodore Capital LP Purchases New Position in Century Therapeutics, Inc. $IPSC - MarketBeat
Century Therapeutics Inc (IPSC) Cash Flow - TradingKey
IPSC|Century Therapeutics Inc|Price:2.110|Chg%:-0.060 - TradingKey
Century Therapeutics Inc (IPSC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Century Therapeutics Inc (IPSC) Institutional Confidence - TradingKey
Century Therapeutics, Inc. Revenue Breakdown – NASDAQ:IPSC - TradingView
Century Therapeutics Inc Azioni (IPSC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):